Anavex Life Sciences CORP 10-Q quarterly reports

Anavex Life Sciences reported a reduced net loss in Q1 2026, bolstered by a $36.3 million equity raise, while its Alzheimer's drug, blarcamesine, faces an EMA re-examination after a negative trend-vote.

Anavex Life Sciences Corp. reported an increased net loss for Q3 2025, alongside significant progress in its Alzheimer's and schizophrenia clinical programs and new capital raising initiatives.

Anavex Life Sciences Corp. files its 10-Q report for the quarter ended March 31, 2025, detailing financial results and providing updates on its clinical development programs.

Anavex Life Sciences Corp. reports a net loss for Q1 2025, alongside updates on its clinical trials for ANAVEX2-73 and ANAVEX3-71.

Anavex Life Sciences Corp. released its Q3 2024 financial results, detailing ongoing clinical trials and financial status.

Anavex Life Sciences Corp. released its financial results for the second quarter of 2024, alongside updates on its clinical development programs.

Anavex Life Sciences reported a net loss of $8.6 million for the first quarter of fiscal year 2024, with a decrease in research and development expenses and an increase in other income.